GLP-1 Prior Authorization Denied? What Comes Next

Having a GLP-1 prior authorization denied means the plan has refused to pay under its rules. It does not, by itself, mean your doctor decided treatment was wrong for you. The next step depends on whether the letter identifies missing records, an unmet coverage rule, or an excluded benefit.

Prior authorization is the plan's review before it agrees to pay. GLP-1 medicines act on a gut-hormone signal involved in appetite and blood sugar. A prescription and permission from insurance are separate decisions.

GLP-1 prior authorization denied: which reason?

The useful starting point is the written denial, rather than the pharmacy's short rejection message. The letter should identify the reason, the rule applied, and how to challenge the decision. HealthCare.gov explains how to challenge a health plan decision.

A formulary is the plan's covered-drug list. A medicine appearing there does not necessarily mean every use is covered. A Medicare study of Ozempic, Mounjaro, and Rybelsus shows how coverage and prior authorization can coexist. Insurance dropping GLP-1 coverage is a different problem from an incomplete first request.

What a Zepbound medical necessity denial needs

“Medical necessity” means the plan's judgment that treatment meets its coverage requirements. A useful response addresses the particular requirement it says was missed.

Depending on that requirement, the prescriber's office may need dated height and weight records, documented conditions, or previous treatment records. BMI, a weight-to-height measure, may be part of the checklist. If the rule requires another treatment first, called step therapy, the relevant records include what was tried and why it stopped.

A letter saying treatment would help is less specific than evidence addressing the disputed rule. The plan can clarify whether additional information belongs in a corrected request or a formal appeal. The plan also needs to clarify whether resubmitting affects the appeal deadline.

Zepbound contains tirzepatide. Promise's compounded tirzepatide, prepared by a pharmacy for an individual prescription, is a separate product. Zepbound coverage does not transfer to that preparation. The tirzepatide insurance guide covers the broader payment distinctions.

Which appeal deadline applies?

An internal appeal asks the plan to reconsider. The HealthCare.gov internal appeals guide describes 180 days after receiving a denial to file. It describes 30 days for a decision on an appeal concerning care not yet received. Those figures describe that federal appeals framework, not every prescription benefit.

Medicare Part D is Medicare's outpatient prescription benefit. It and Medicaid, the joint federal and state health program, have their own appeal procedures. Since July 1, 2026, the separate Medicare GLP-1 Bridge has covered selected weight-management GLP-1 medicines for eligible beneficiaries through its own centralized prior authorization process; the tirzepatide insurance guide explains it. The denial notice and plan documents identify the applicable deadline, submission address, and review stages. For job-based coverage, the plan administrator can identify which rules govern the benefit.

External review asks an independent reviewer to examine an eligible dispute. External review is not available for every kind of disagreement. Under the federal framework HealthCare.gov describes, an insurer must speed up review when the standard timeline could seriously jeopardize the patient's life or ability to regain maximum function; the clinician's explanation of that risk supports the request.

As of November 5, 2026, the day this article was written, the September 2026 summary from CMS, the federal Medicare and Medicaid agency still lists its April 10, 2026 proposal to set prior authorization decision deadlines for drugs in some plans (not Medicare Part D) as a proposal, not a final rule. Its existing seven-day decision rule for prior authorization of medical services excludes drugs. That rule does not set a GLP-1 drug appeal deadline.

What belongs in a Wegovy prior authorization appeal?

Wegovy contains semaglutide. Its appeal needs the exact denied product, the reason it was prescribed, and evidence matching the plan's written criteria. A different semaglutide brand is not automatically the same insurance request.

A useful submission includes:

• The denial notice, member details, and request reference number.
• The specific criterion being disputed and the prescriber's explanation.
• Relevant chart notes, test results, or treatment history, with dates.
• Any authorization required for someone else to appeal on the patient's behalf.
• Copies of submitted material and proof the plan received it.

HealthCare.gov also recommends keeping notes of conversations, including names, dates, and what was said. That record helps when the office and plan disagree about what arrived.

Promise's compounded semaglutide is a separate pharmacy preparation from Wegovy. A successful Wegovy appeal would concern the branded prescription; it would not establish payment for compounded semaglutide.

What recent denial studies actually tell us

As of November 5, 2026, the day this article was written, an October 15, 2026 study in Health Affairs Scholar offers a useful caution. Across 2018–2024, about one-third, or 34.1%, of people with an initially denied GLP-1 claim obtained a paid fill within 90 days. In the 2024 group, that figure was about one-quarter, or 24.8%.

The study could not separate successful appeals from corrected submissions, new prescriptions, or changes to another medicine. That measures paid prescriptions, not appeal success rates. It also could not distinguish missing authorization from exclusions and other rejection reasons.

As of November 5, 2026, the day this article was written, a study first published August 10, 2026 in Diabetes, Obesity and Metabolism examined 8,821 later-stage Medicare Part D appeals. Fewer than one in five appeals in its 2025 data ended favorably. It studied Ozempic, Rybelsus, and Mounjaro, excluding Wegovy and Zepbound.

Those cases had already reached independent review after a plan-level appeal. They cannot predict the outcome of a first appeal for a different product or plan.

Who prescribes, pays, and dispenses?

The prescriber explains the medical reasoning. The plan decides payment under its benefits. The pharmacy processes the prescription and any claim; it cannot change a benefit exclusion.

The FDA distinguishes compounded medicines from reviewed brand products. Promise's semaglutide and tirzepatide are dispensed by a licensed U.S. compounding pharmacy as compounded medications, different from an FDA-approved product: the formulations offered here are not FDA-approved.

A licensed provider may still prescribe — that decision is between you and your doctor. That decision does not create insurance reimbursement. Compounded tirzepatide is generally self-pay. Choosing it does not reverse a brand denial.

Today's appeal and next year's benefits

Appealing today's decision asks whether the current rules were applied correctly. Open enrollment GLP-1 coverage concerns choosing next year's benefits. A future plan change does not resolve a current denial.

A useful question for the plan is: “Which exact requirement was not met, and which document would address it?” If the answer is an exclusion, the next question is where that exclusion appears in the benefit documents.

The prescriber's office can confirm what it submitted and whether it will handle the appeal. The pharmacy can clarify whether its message reflects a formal denial or an authorization still missing from the system.

When several people are helping, an agreed owner for the next submission avoids each office expecting the other to act. A saved receipt confirms what actually reached the plan.

The immediate record is simpler: the exact reason, the evidence needed, the filing deadline, and who is responsible for the next submission. None promises approval, but each makes the next step clearer.

At Promise, a licensed provider reviews every request and may prescribe or decline; not everyone qualifies.